OraSure Technologies Provides Update on Clinical Development Programs and OraQuick Manufacturing

Business Wire, June 25, 2009

BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced an update regarding the status of its application for U.S. Food and Drug Administration (“FDA”) approval of an OraQuick® Hepatitis C (“HCV”) test for professional use and its clinical program for an OraQuick® HIV-1/2 test for sale in the consumer or over-the-counter (“OTC”) market. In addition, the Company announced its efforts to address manufacturing challenges recently experienced with respect to its OraQuick ADVANCE® rapid HIV-1/2 antibody test.

OraQuick® HCV Test

During the fourth quarter of 2008, the Company filed a premarket approval application (“PMA”) with the FDA for approval of an OraQuick® HCV test for use in the professional market. The application sought approval for use of the product with multiple specimen types, including venous whole blood, fingerstick whole blood, oral fluid and other sample types. The clinical study data submitted in the PMA showed a high degree of correlation to the comparator assay conducted at a central laboratory.

Since filing its PMA, the Company has been in frequent communications with the FDA and has received a number of questions and requests for additional information from the agency. During its review of the PMA, the FDA indicated that the Company’s clinical data could potentially have been affected by bias because the same operators performed the test and interpreted the results on multiple specimen types derived from the same patient. The FDA had previously reviewed and concurred with the Company’s original clinical trial protocol, which had stated that the study would not be blinded to prevent an operator from seeing the results of multiple devices used on the same patient, but would be blinded as to central laboratory results using an FDA-approved comparator assay.

When the agency later raised concerns during the PMA review regarding potential interpretation bias, the Company reasonably expected to be able to address these concerns without material impact to the clinical program because the Company had executed the clinical program as designed. However, the FDA recently concluded that additional clinical testing will be required to obtain approval of the PMA for a venous whole blood claim, and that a new clinical study will be required for approval of claims for oral fluid and other sample types.

Although the Company believes the clinical data originally submitted to the FDA is sufficient to support approval of its PMA, the Company has agreed to conduct the additional clinical testing and study mandated by the FDA in order to obtain approved claims for oral fluid, venous whole blood, and fingerstick whole blood. The exact timing and costs associated with this work will not be fully determined until after protocols are submitted and reviewed by the FDA, which should occur in the next several weeks. The Company expects first to complete the additional testing required for a venous whole blood claim and submit that data to the FDA for review and approval, while the additional study for the other specimen types is completed. The Company believes that it has adequately responded to all other questions and requests for information received to date from the FDA with respect to the OraQuick® HCV PMA submission.

The Company also plans to submit its application for CE mark for the OraQuick® HCV test shortly. A CE mark is required in order to sell the product in Europe.

The Company expects to record a non-cash impairment charge of $3.0 million related to a portion of the milestone payments previously made under a license for certain HCV patents. These milestone payments were initially recorded as capital assets. The Company believes that, in light of the absence of sales in the international marketplace of a rapid HCV test that is subject to that license, coupled with expected delays in FDA approval of the Company’s OraQuick® HCV test as described above, such a non-cash charge should be taken. The charge is expected to be reflected in the financial results for the second quarter as an operating expense and was not previously included in the Company’s financial guidance for this period.

OraQuick® HIV OTC Test

In August 2008, the Company submitted the results of its observed use study to the FDA as part of its efforts to obtain approval for an OraQuick® rapid HIV OTC test. The observed use study was designed to assess an individual’s ability to interact with the product packaging, comprehend the instructions for use, take the test and interpret the results while a trained professional observed those activities. The observed use study was stopped after testing was completed for the first 1,000 subjects, because data from the study met the success criteria initially established in the study protocol for this phase of the trials.